Evidence map›Paper›PMID 28367765›Full record

Trial reportThe British journal of nutrition2017

Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial.

Kristin L Wickens, Christine A Barthow, Rinki Murphy, Peter R Abels, Robyn M Maude, Peter R Stone, Edwin A Mitchell, Thorsten V Stanley, Gordon L Purdie, Janice M Kang and 5 more

4 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 83 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03407157 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization

TypeinterventionalSponsorUniversity of British ColumbiaRan2020 to 2024Enrolled168ConditionsGroup B Streptococcus Carrier in ChildbirthArmsProbiotic supplementation, Placebo
NCT07439978 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Physiological Study of a Fermented Yogurt Drink Containing Probiotics

TypeinterventionalSponsorUniversity College DublinRan2026 to 2026Enrolled50ConditionsColonization, Asymptomatic, ColonisationArmsprobiotic containing L.rhamnosus R0011 strain, 200 ml yogurt drink
NCT07510282 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Physiological Study on How Probiotic Delivered to the Small Intestine Changes Microbiota

TypeinterventionalSponsorUniversity College DublinRan2026 to 2026Enrolled25ConditionsColonization, Asymptomatic, ColonizationArmsProbiotic containing L.rhamnosus R0011 strain, 200 ml yogurt drink
NCT07679490 naactive not recruitingnot on this mapstarted 2026, after this paper: background citation

A Physiological Study of a Fruit Snack Containing Probiotics

TypeinterventionalSponsorUniversity College DublinRan2026 to 2027Enrolled25ConditionsColonization, Asymptomatic, Probiotic Intervention, Gut Microbiota Diversity and Composition, Gut-brain AxisArmsMicroencapsulated Lactobacillus rhamnosus Fruit Snack, Placebo Fruit Snack
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Probiotics for preventing gestational diabetes.The Cochrane database of systematic reviews · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. The role of gut micorbiome in obesity and diabetes.World journal of pediatrics : WJP · 2019
    Pooled it
  13. Pooled it
  14. Effects ofNutrients · 2024
    Trial
  15. Trial
  16. Trial
  17. Effect ofNutrients · 2021
    Trial
  18. Trial
  19. Trial
  20. Trial

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kristin L Wickens1University of Otago,Wellington 6021,New Zealand.
Christine A Barthow1University of Otago,Wellington 6021,New Zealand.
Rinki Murphy2University of Auckland,Auckland 1142,New Zealand.
Peter R Abels1University of Otago,Wellington 6021,New Zealand.
Robyn M Maude4Victoria University,Wellington 6021,New Zealand.
Peter R Stone2University of Auckland,Auckland 1142,New Zealand.
Edwin A Mitchell2University of Auckland,Auckland 1142,New Zealand.
Thorsten V Stanley1University of Otago,Wellington 6021,New Zealand.
Gordon L Purdie1University of Otago,Wellington 6021,New Zealand.
Janice M Kang1University of Otago,Wellington 6021,New Zealand.
Fiona E Hood1University of Otago,Wellington 6021,New Zealand.
Judy L Rowden2University of Auckland,Auckland 1142,New Zealand.
Phillipa K Barnes1University of Otago,Wellington 6021,New Zealand.
Penny F Fitzharris5Auckland Hospital,Auckland 1142,New Zealand.
Julian Crane1University of Otago,Wellington 6021,New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 (HN001) can reduce the prevalence of gestational diabetes mellitus (GDM). A double-blind, randomised, placebo-controlled parallel trial was conducted in New Zealand (NZ) (Wellington and Auckland). Pregnant women with a personal or partner history of atopic disease were randomised at 14-16 weeks' gestation to receive HN001 (6×109 colony-forming units) (n 212) or placebo (n 211) daily. GDM at 24-30 weeks was assessed using the definition of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (fasting plasma glucose ≥5·1 mmol/l, or 1 h post 75 g glucose level at ≥10 mmol/l or at 2 h ≥8·5 mmol/l) and NZ definition (fasting plasma glucose ≥5·5 mmol/l or 2 h post 75 g glucose at ≥9 mmol/l). All analyses were intention-to-treat. A total of 184 (87 %) women took HN001 and 189 (90 %) women took placebo. There was a trend towards lower relative rates (RR) of GDM (IADPSG definition) in the HN001 group, 0·59 (95 % CI 0·32, 1·08) (P=0·08). HN001 was associated with lower rates of GDM in women aged ≥35 years (RR 0·31; 95 % CI 0·12, 0·81, P=0·009) and women with a history of GDM (RR 0·00; 95 % CI 0·00, 0·66, P=0·004). These rates did not differ significantly from those of women without these characteristics. Using the NZ definition, GDM prevalence was significantly lower in the HN001 group, 2·1 % (95 % CI 0·6, 5·2), v. 6·5 % (95 % CI 3·5, 10·9) in the placebo group (P=0·03). HN001 supplementation from 14 to 16 weeks' gestation may reduce GDM prevalence, particularly among older women and those with previous GDM.

Indexed as

Lacticaseibacillus rhamnosusAdultBlood GlucoseDiabetes, GestationalDouble-Blind MethodFemaleHumansNew ZealandPregnancyPrevalenceProbioticsBlood GlucoseFonterra Fonterra Co-operative Group LtdGDM gestational diabetes mellitusGestational diabetes mellitusGTT glucose tolerance testHN001 Lactobacillus rhamnosus HN001IADPSG International Association of Diabetes and Pregnancy Study GroupLactobacillus rhamnosus HN001NZ New ZealandProbioticsRandomised controlled trialsRR relative rate

Identifiers

PMID28367765
PMCPMC5426322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.